[Infectious keratitis and cosmetic lenses: a five-case retrospective study].
OBJECTIVE
To determine the characteristics of infectious keratitis related to plano cosmetic lenses.


METHODS
Retrospective case study of a series of infectious keratitis among plano cosmetic lenses wearers. The main parameters were demographic data, medical history, risk factors for infectious complications and keratitis severity criteria, microbiological results, clinical course, and final visual acuity.


RESULTS
Five patients were included, all females, ranging from 15 to 50 years of age. Four were emmetropic. One patient had undergone refractive photokeratectomy a few months before. All had risk factors for infectious complications. The fundamental causes of infections were diverse: bacterial abscesses, keratomycosis, and amoebic keratitis. All presented severity criteria. In two cases, the keratitis led to severe consequences with legal blindness requiring penetrating keratoplasty in one case.


CONCLUSIONS
Infectious keratitis in plano cosmetic lenses wearers is not rare and may have dramatic consequences. Sales are specifically regulated and the lenses are considered cosmetic products, not medical devices. The sales regulations for plano cosmetic lenses should be updated, as several countries have already done after encountering many serious incidents.
Guyomarch
J
J
Service d'Ophtalmologie, Centre Hospitalier Universitaire de Fort-de-France.
van Nuoï
D N'guyen
DN
Beral
L
L
Donnio
A
A
Desbois
N
N
Olive
C
C
Theodose
R
R
Merle
H
H
D000038:Abscess / Q000382:microbiology; D015823:Acanthamoeba Keratitis / Q000469:parasitology; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D001550:Benzamidines / Q000627:therapeutic use; D001645:Biguanides / Q000627:therapeutic use; D001766:Blindness / Q000209:etiology; D003261:Contact Lenses / Q000009:adverse effects*; D003318:Corneal Opacity / Q000209:etiology; D048988:Corneal Surgery, Laser; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D007634:Keratitis / Q000382:microbiology*; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000382:microbiology; D011743:Pyrimidines / Q000627:therapeutic use; D012189:Retrospective Studies; D012307:Risk Factors; D016868:Serratia Infections / Q000382:microbiology; D013203:Staphylococcal Infections / Q000382:microbiology; D013982:Ticarcillin / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use; D014640:Vancomycin / Q000627:therapeutic use; D065819:Voriconazole; D055815:Young Adult
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000891:Anti-Infective Agents, Local; D000935:Antifungal Agents; D001550:Benzamidines; D001645:Biguanides; D005839:Gentamicins; D011743:Pyrimidines; D014230:Triazoles; C031233:polihexanide; C018961:hexamidine; D014640:Vancomycin; D013982:Ticarcillin; D065819:Voriconazole